Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Russian drone slams into block of flats in deadly wave of strikes across Kyiv - 2Pick the Ideal Family Feline Variety for Your Home
- 3Scientists map of old Mars river basins for the 1st time. These could be great places to search for ancient life
- 4Exemplary Fragrances: A Manual for Notorious Scents
- 5Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- The most effective method to Oversee Unsold SUVs in the Car Business
- 7 Fast Approaches to Let loose Space on Your Telephone in a flash
- Dominating the Art of Composing: Creator Bits of knowledge
- The most effective method to Guarantee Simple Availability in Seniors' SUVs
- Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
- Get away from the Tedious Drudgery: Go into Business Today!
- A few Exemplary Chinese Dishes, Which Are Famous Around the world
- Instructions to Choose the Best Material Organization for a Fruitful Rooftop Substitution
- 7 Powerful Methods for forestalling Telephone Overheating: Keep Your Gadget Cool
